On Oct. 7, Baxter updated its website with information on shipments. The website says:
“We have resumed shipments to hospitals and dialysis patients after the temporary hold last week, based on allocations as previously communicated. We have moved finished goods from our North Cove site that were not impacted by the storm and are inspecting other finished goods onsite. This inventory will be used to support current allocations in the short term. Several of our global plants are scaling and ramping production to help meet U.S. needs, and we expect to receive product from these sources throughout the month of October. We will communicate adjustments to allocations within the next two weeks as we assess timing of inbound products and shipments.”
Baxter also said that they are continuing to work with ASPR and FDA on special importation requirements for certain sites and products located outside of the U.S. The organization says they are not expected to be filed as Emergency Use Authorizations but as special importation license.
“We are grateful for the support of and continued collaboration with the U.S. Government in our efforts to support U.S. patients,” the release adds.
The organization also thanks its customers and partners.
We’ve been covering the news.
Janette Wider | Editor-in-Chief
Janette Wider is Editor-in-Chief for Healthcare Purchasing News.
